PolyPid Ltd. Overview
Pro stress-test →PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months.
Strategic Profile
Pro stress-test →PolyPid's lead product candidate D-PLEX 100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In March 2026, PolyPid submitted first modules as part of a rolling NDA review, with completion expected in Q2 2026, and received a $4.3 million FDA Small Business Waiver to enable focus on commercialization preparations.
Competitive Landscape
Pro stress-test →PolyPid pursues a focused biotech model built around proprietary delivery technology for locally administered therapies addressing post-surgical infections and oncology indications. The company competes within the surgical site infection prevention and specialty oncology drug delivery markets, where competitors include established pharmaceutical companies developing preventive and therapeutic agents. No verified analyst coverage was identified.
Industry Context
PolyPid Ltd. operates in Biopharmaceutical - Specialty Drug Delivery.
Key facts
Founded: N/A · Headquarters: Petach Tikva, Israel · Employees: N/A · Revenue: N/A · Market cap: N/A